We are live on ! Find out more
HELP

Helus Pharma Inc. Common Stock
HELP

50 hedge funds and large institutions have $51.9M invested in Helus Pharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

13.88% more ownership

Funds ownership: 0% → 13.88% (+14%)

Holders
50
Holders Change
+50
Holders Change %
–
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
50
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$31M
2
Citadel Advisors
Citadel Advisors
Florida
+$11.6M
3
PCC
Perry Creek Capital
New York
+$6.58M
4
SSA
Schonfeld Strategic Advisors
New York
+$1.73M
5
MS
Maven Securities
Jersey
+$921K

Top Sellers

No sellers this quarter

HELP Hedge Fund Activity: Q3 2021 in Review

50 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q3 2021, worth a combined $51.9M.

Buyers outnumbered sellers: 50 funds opened new HELP positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $31M.

  • 50 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $51.9M of Helus Pharma Inc. Common Stock stock for Q3 2021.
  • 50 funds opened new Helus Pharma Inc. Common Stock positions in Q3 2021 and 0 closed out, a net change of +50 holders.
  • The largest Helus Pharma Inc. Common Stock buyer in Q3 2021 was OrbiMed, an estimated $31M added.

Based on aggregated 13F filings for Q3 2021.